Galecto
GLTO2.020
▲0.010
▲0.50%
- 最高位
- 2.050
- 最低位
- 2.020
- 開市價
- --
- 前收市價
- 2.010
- 成交量(千)
- 0.11
- 成交額(百萬)
- 0.00
- 買入
- --
- 賣出
- --
- 每手股數
- --
- 市值(百萬)
- 51.30
- 市盈率
- --
- 息率
- --
- 差價
- --
- 52週高低
- 4.680 - 1.170
所有資料不保證絕對正確、完整、或實時，僅作為參考使用。投資涉及風險，過往業績並不代表將來表現，作任何投資決定或交易前，閣下應諮詢獨立專業意見。所有內容均不構成投資建議。
企業資料
- 公司名稱
- Galecto
- 證券代碼
- GLTO.US
- 所屬板塊
- Biotechnology
- 公司業務
- Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
- 發行量
- 25261832
- 公司總部
- Ole Maaloes Vej 3
- 公司網址
- https://www.galecto.com
- 公司電郵
- info@galecto.com
- 公司電話
- +45 70705210
暫無內容
關於
Galecto(GLTO.US)所屬的行業板塊為Biotechnology。
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
詳細公司背景可參考: https://www.galecto.com。